Concepts (234)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 29 | 2025 | 1092 | 5.450 |
Why?
|
| Transcription Factors | 18 | 2019 | 735 | 3.510 |
Why?
|
| Cathepsin L | 7 | 2019 | 15 | 2.500 |
Why?
|
| HMGA2 Protein | 3 | 2025 | 9 | 2.380 |
Why?
|
| Vitis | 4 | 2019 | 37 | 1.910 |
Why?
|
| Plant Extracts | 5 | 2019 | 302 | 1.650 |
Why?
|
| Homeodomain Proteins | 5 | 2019 | 150 | 1.640 |
Why?
|
| Cell Line, Tumor | 30 | 2025 | 2676 | 1.590 |
Why?
|
| Repressor Proteins | 3 | 2019 | 273 | 1.340 |
Why?
|
| Cell Nucleus | 4 | 2020 | 383 | 1.320 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2025 | 968 | 1.300 |
Why?
|
| Cell Movement | 16 | 2020 | 655 | 1.170 |
Why?
|
| Bone Neoplasms | 4 | 2019 | 49 | 1.100 |
Why?
|
| Breast Neoplasms | 10 | 2023 | 1723 | 1.060 |
Why?
|
| Neoplasm Metastasis | 6 | 2023 | 237 | 1.050 |
Why?
|
| Reactive Oxygen Species | 5 | 2024 | 532 | 0.910 |
Why?
|
| Nuclear Proteins | 2 | 2017 | 333 | 0.890 |
Why?
|
| Oxidative Stress | 7 | 2024 | 1003 | 0.840 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 112 | 0.840 |
Why?
|
| Serpins | 4 | 2012 | 27 | 0.820 |
Why?
|
| Male | 33 | 2025 | 23409 | 0.790 |
Why?
|
| Thiazoles | 2 | 2014 | 76 | 0.780 |
Why?
|
| Cell Adhesion | 5 | 2020 | 238 | 0.760 |
Why?
|
| Indoles | 2 | 2014 | 187 | 0.710 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2014 | 134 | 0.710 |
Why?
|
| Subcellular Fractions | 3 | 2017 | 77 | 0.700 |
Why?
|
| Humans | 45 | 2025 | 43102 | 0.690 |
Why?
|
| STAT3 Transcription Factor | 2 | 2019 | 102 | 0.670 |
Why?
|
| Protease Inhibitors | 2 | 2017 | 54 | 0.630 |
Why?
|
| Epithelial Cells | 7 | 2012 | 434 | 0.610 |
Why?
|
| CCAAT-Binding Factor | 1 | 2019 | 3 | 0.610 |
Why?
|
| Peroxidase | 1 | 2019 | 57 | 0.600 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2019 | 78 | 0.580 |
Why?
|
| Cell Proliferation | 9 | 2020 | 1455 | 0.580 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2015 | 299 | 0.560 |
Why?
|
| Estrogen Receptor alpha | 1 | 2019 | 121 | 0.560 |
Why?
|
| Mesoderm | 5 | 2017 | 73 | 0.560 |
Why?
|
| Signal Transduction | 11 | 2019 | 2157 | 0.560 |
Why?
|
| Neoplasm Invasiveness | 8 | 2017 | 290 | 0.550 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 3 | 2014 | 105 | 0.540 |
Why?
|
| beta Karyopherins | 1 | 2017 | 4 | 0.540 |
Why?
|
| Nuclear Localization Signals | 1 | 2017 | 15 | 0.530 |
Why?
|
| Prostate | 3 | 2018 | 155 | 0.520 |
Why?
|
| Dipeptides | 1 | 2017 | 31 | 0.520 |
Why?
|
| MAP Kinase Signaling System | 1 | 2018 | 196 | 0.500 |
Why?
|
| Apoptosis | 9 | 2020 | 1568 | 0.480 |
Why?
|
| Cadherins | 5 | 2018 | 102 | 0.470 |
Why?
|
| Autophagy | 1 | 2016 | 140 | 0.460 |
Why?
|
| Anticarcinogenic Agents | 1 | 2015 | 77 | 0.440 |
Why?
|
| RNA, Small Interfering | 4 | 2019 | 436 | 0.430 |
Why?
|
| Mice, Nude | 5 | 2019 | 408 | 0.430 |
Why?
|
| Cathepsin D | 1 | 2014 | 16 | 0.430 |
Why?
|
| Cell Survival | 5 | 2020 | 945 | 0.420 |
Why?
|
| Superoxides | 1 | 2014 | 57 | 0.420 |
Why?
|
| RANK Ligand | 3 | 2015 | 19 | 0.420 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2011 | 137 | 0.390 |
Why?
|
| Arabidopsis | 1 | 2014 | 103 | 0.390 |
Why?
|
| Sesquiterpenes | 1 | 2012 | 38 | 0.380 |
Why?
|
| Transfection | 6 | 2012 | 532 | 0.340 |
Why?
|
| Integrins | 1 | 2011 | 54 | 0.340 |
Why?
|
| Gene Expression Regulation | 2 | 2025 | 1070 | 0.330 |
Why?
|
| Chromogranin A | 1 | 2010 | 7 | 0.330 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2010 | 33 | 0.320 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 223 | 0.320 |
Why?
|
| Promoter Regions, Genetic | 4 | 2019 | 526 | 0.320 |
Why?
|
| Mice | 7 | 2020 | 6644 | 0.320 |
Why?
|
| Proteins | 2 | 2003 | 382 | 0.320 |
Why?
|
| Cell Differentiation | 2 | 2010 | 638 | 0.310 |
Why?
|
| Breast | 2 | 2018 | 139 | 0.300 |
Why?
|
| Transcription, Genetic | 4 | 2019 | 592 | 0.300 |
Why?
|
| Antineoplastic Agents | 5 | 2025 | 1019 | 0.290 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2008 | 165 | 0.280 |
Why?
|
| Disease Progression | 6 | 2018 | 667 | 0.280 |
Why?
|
| Carcinoma | 1 | 2008 | 108 | 0.270 |
Why?
|
| Phosphorylation | 5 | 2019 | 986 | 0.260 |
Why?
|
| Feedback, Physiological | 2 | 2017 | 32 | 0.250 |
Why?
|
| RNA Interference | 3 | 2019 | 247 | 0.250 |
Why?
|
| Gene Silencing | 2 | 2020 | 154 | 0.250 |
Why?
|
| Animals | 10 | 2020 | 16992 | 0.240 |
Why?
|
| Pyridines | 2 | 2019 | 139 | 0.240 |
Why?
|
| In Situ Hybridization | 1 | 2025 | 138 | 0.240 |
Why?
|
| Proteomics | 2 | 2019 | 378 | 0.230 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2016 | 76 | 0.230 |
Why?
|
| Carcinogens, Environmental | 2 | 2015 | 35 | 0.230 |
Why?
|
| Cell Communication | 2 | 2020 | 114 | 0.210 |
Why?
|
| Lipid Peroxidation | 1 | 2024 | 140 | 0.210 |
Why?
|
| Caspase 3 | 2 | 2016 | 227 | 0.210 |
Why?
|
| Vimentin | 2 | 2018 | 44 | 0.200 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2014 | 79 | 0.200 |
Why?
|
| Time Factors | 5 | 2014 | 1857 | 0.190 |
Why?
|
| Receptors, Androgen | 4 | 2014 | 144 | 0.190 |
Why?
|
| Osteoclasts | 2 | 2015 | 28 | 0.190 |
Why?
|
| Extracellular Matrix | 3 | 2012 | 131 | 0.180 |
Why?
|
| Tyrosine | 1 | 2002 | 120 | 0.180 |
Why?
|
| Poverty | 1 | 2025 | 400 | 0.180 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2024 | 307 | 0.180 |
Why?
|
| Aged | 3 | 2025 | 8214 | 0.180 |
Why?
|
| Capacity Building | 1 | 2022 | 99 | 0.180 |
Why?
|
| Protein Transport | 3 | 2020 | 296 | 0.170 |
Why?
|
| Middle Aged | 4 | 2025 | 12222 | 0.170 |
Why?
|
| Female | 9 | 2025 | 24698 | 0.160 |
Why?
|
| Community-Institutional Relations | 1 | 2022 | 219 | 0.160 |
Why?
|
| Gluconeogenesis | 1 | 2019 | 15 | 0.150 |
Why?
|
| Tyrphostins | 1 | 2019 | 15 | 0.150 |
Why?
|
| Egtazic Acid | 1 | 2019 | 13 | 0.150 |
Why?
|
| Durapatite | 1 | 2019 | 18 | 0.150 |
Why?
|
| Adaptation, Physiological | 1 | 2020 | 143 | 0.150 |
Why?
|
| Gene Knockdown Techniques | 2 | 2017 | 189 | 0.150 |
Why?
|
| Metabolomics | 1 | 2019 | 95 | 0.140 |
Why?
|
| Up-Regulation | 3 | 2016 | 536 | 0.140 |
Why?
|
| Down-Regulation | 3 | 2016 | 456 | 0.140 |
Why?
|
| Bone and Bones | 1 | 2019 | 114 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2010 | 652 | 0.140 |
Why?
|
| Microscopy, Fluorescence | 2 | 2016 | 256 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 590 | 0.130 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2017 | 60 | 0.130 |
Why?
|
| Mice, Inbred BALB C | 1 | 2019 | 694 | 0.130 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2018 | 100 | 0.130 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2010 | 108 | 0.130 |
Why?
|
| Caspase 12 | 1 | 2016 | 5 | 0.130 |
Why?
|
| Tissue Distribution | 1 | 2017 | 240 | 0.130 |
Why?
|
| Chloroquine | 1 | 2016 | 19 | 0.130 |
Why?
|
| Cell Line | 1 | 2020 | 1410 | 0.130 |
Why?
|
| Blotting, Western | 3 | 2010 | 883 | 0.130 |
Why?
|
| Cathepsins | 1 | 2016 | 9 | 0.130 |
Why?
|
| Cystatin C | 1 | 2016 | 25 | 0.130 |
Why?
|
| Leucine | 1 | 2016 | 31 | 0.120 |
Why?
|
| Antigens, CD | 1 | 2017 | 127 | 0.120 |
Why?
|
| Heat-Shock Proteins | 1 | 2016 | 57 | 0.120 |
Why?
|
| Neoplasms | 2 | 2019 | 1377 | 0.120 |
Why?
|
| Health Status Disparities | 1 | 2023 | 719 | 0.120 |
Why?
|
| Calcium | 1 | 2019 | 491 | 0.120 |
Why?
|
| Environmental Exposure | 2 | 2015 | 256 | 0.120 |
Why?
|
| Organ Specificity | 2 | 2014 | 141 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2016 | 152 | 0.120 |
Why?
|
| Osteoprotegerin | 1 | 2015 | 16 | 0.120 |
Why?
|
| Hazardous Substances | 1 | 2015 | 19 | 0.110 |
Why?
|
| Chemoprevention | 1 | 2015 | 41 | 0.110 |
Why?
|
| Osteogenesis | 1 | 2015 | 57 | 0.110 |
Why?
|
| Models, Biological | 2 | 2017 | 712 | 0.110 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2005 | 61 | 0.110 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 704 | 0.110 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2016 | 241 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2019 | 502 | 0.110 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2013 | 59 | 0.110 |
Why?
|
| Gene Expression | 3 | 2012 | 701 | 0.100 |
Why?
|
| Cytokines | 1 | 2018 | 678 | 0.100 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2014 | 116 | 0.100 |
Why?
|
| Imidazoles | 1 | 2014 | 142 | 0.100 |
Why?
|
| Lysosomes | 1 | 2014 | 86 | 0.100 |
Why?
|
| Protein Binding | 1 | 2017 | 1082 | 0.100 |
Why?
|
| Neurons | 1 | 2020 | 1263 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 1124 | 0.100 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2013 | 20 | 0.100 |
Why?
|
| Caspase 7 | 1 | 2012 | 18 | 0.100 |
Why?
|
| Enzyme Activation | 1 | 2014 | 462 | 0.100 |
Why?
|
| Caribbean Region | 2 | 2025 | 79 | 0.100 |
Why?
|
| Rats | 1 | 2020 | 3735 | 0.100 |
Why?
|
| NF-kappa B | 2 | 2020 | 358 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2014 | 220 | 0.090 |
Why?
|
| Transcriptional Activation | 1 | 2012 | 173 | 0.090 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 2853 | 0.090 |
Why?
|
| Integrin alpha2 | 1 | 2011 | 3 | 0.090 |
Why?
|
| Integrin alpha5 | 1 | 2011 | 2 | 0.090 |
Why?
|
| Neoplasm Transplantation | 2 | 2008 | 129 | 0.090 |
Why?
|
| Receptors, CXCR4 | 1 | 2010 | 74 | 0.080 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 196 | 0.080 |
Why?
|
| Receptor Cross-Talk | 1 | 2009 | 18 | 0.080 |
Why?
|
| Flow Cytometry | 1 | 2011 | 411 | 0.080 |
Why?
|
| Androgens | 1 | 2010 | 106 | 0.080 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2009 | 12 | 0.070 |
Why?
|
| Smad Proteins | 1 | 2009 | 12 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 3 | 2008 | 508 | 0.070 |
Why?
|
| Antioxidants | 1 | 2012 | 443 | 0.070 |
Why?
|
| Cell Dedifferentiation | 1 | 2008 | 4 | 0.070 |
Why?
|
| Bone Remodeling | 1 | 2008 | 24 | 0.070 |
Why?
|
| Epidermal Growth Factor | 1 | 2008 | 70 | 0.070 |
Why?
|
| Mice, SCID | 1 | 2008 | 158 | 0.070 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2008 | 97 | 0.070 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2008 | 81 | 0.070 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2006 | 20 | 0.060 |
Why?
|
| DNA, Complementary | 2 | 2008 | 196 | 0.060 |
Why?
|
| Stromal Cells | 1 | 2006 | 55 | 0.060 |
Why?
|
| Cells, Cultured | 1 | 2010 | 1621 | 0.060 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2005 | 4 | 0.060 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2025 | 157 | 0.060 |
Why?
|
| Receptors, Cell Surface | 1 | 2005 | 146 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2006 | 291 | 0.050 |
Why?
|
| Kenya | 1 | 2023 | 58 | 0.050 |
Why?
|
| p21-Activated Kinases | 1 | 2003 | 21 | 0.050 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2003 | 28 | 0.050 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2003 | 50 | 0.050 |
Why?
|
| Phenotype | 2 | 2020 | 780 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2002 | 52 | 0.050 |
Why?
|
| Hospitals | 1 | 2023 | 117 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2023 | 142 | 0.050 |
Why?
|
| Adult | 1 | 2018 | 13872 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 1 | 2002 | 423 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 458 | 0.040 |
Why?
|
| Culture Media, Serum-Free | 1 | 2020 | 44 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 310 | 0.040 |
Why?
|
| Africa | 1 | 2019 | 82 | 0.040 |
Why?
|
| Inflammation | 1 | 2025 | 758 | 0.040 |
Why?
|
| Teaching | 1 | 2019 | 59 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2022 | 363 | 0.040 |
Why?
|
| Community-Based Participatory Research | 1 | 2022 | 352 | 0.040 |
Why?
|
| Cell Cycle | 1 | 2020 | 346 | 0.040 |
Why?
|
| Universities | 1 | 2022 | 559 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 2025 | 749 | 0.040 |
Why?
|
| Registries | 1 | 2019 | 437 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2009 | 934 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2016 | 154 | 0.030 |
Why?
|
| Child | 1 | 2023 | 3443 | 0.030 |
Why?
|
| Androgen Antagonists | 1 | 2014 | 29 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2014 | 159 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2013 | 88 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2013 | 190 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2010 | 209 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2009 | 80 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2009 | 74 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2009 | 181 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2009 | 92 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2009 | 9 | 0.020 |
Why?
|
| Luciferases | 1 | 2009 | 71 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2009 | 148 | 0.020 |
Why?
|
| United States | 1 | 2019 | 5205 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2009 | 183 | 0.020 |
Why?
|
| Plasmids | 1 | 2009 | 244 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2009 | 228 | 0.020 |
Why?
|
| Clone Cells | 1 | 2006 | 50 | 0.020 |
Why?
|
| Environment | 1 | 2006 | 149 | 0.010 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2005 | 10 | 0.010 |
Why?
|
| Cell Hypoxia | 1 | 2005 | 60 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2008 | 1271 | 0.010 |
Why?
|